Evercore ISI Group Upgrades Sarepta Therapeutics to Outperform, Lowers Price Target to $179
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has upgraded Sarepta Therapeutics (NASDAQ:SRPT) from In-Line to Outperform, while lowering the price target from $185 to $179.
August 08, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group has upgraded Sarepta Therapeutics from In-Line to Outperform, while lowering the price target from $185 to $179.
The upgrade to Outperform is a positive signal for investors, indicating that the analyst expects the stock to perform better than the market. However, the lowered price target suggests some caution regarding the stock's potential upside. Overall, the upgrade is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100